fbpx

YOUR GUIDE TO STAYING INFORMED IN THE MARKETS

Subscribe for FREE Email Updates & Access To EXCLUSIVE Research!

Stocks Drive Lower Across The Board During Holiday-Shortened Week – $AAPL $BTC $IYH $KMX $TSLA Rise!

By John F. Heerdink, Jr.
LinkedIn Twitter Disclaimer


Quote of the Day:  “If everyone is moving forward together, then success takes care of itself.” – Henry Ford


Happy Saturday!

I hope that you had a fantastic week. I am glad to report that I made it back safely from my annual camping trip to Samuel P. Taylor Campground in NorCal and spent the balance divided between San Francisco & traveling to the Phoenix area for a couple of our sister organization’s (Tribe Public) CEO Presentation and Q&A events that were held in Scottsdale and Peoria, AZ. The events were co-hosted by Travis Whitfill, MPH MPhil PhD(c), Cofounder and Chief Operating Officer of Azitra, Inc., a company that successfully priced their Initial Public Offering (IPO) on the Nasdaq with the ticker ‘AZTR’ recently on Friday, June 16, 2023 and closed Friday’s trading at $4.28. Mr. Whitfill provided a presentation about Azitra’s precision dermatology platform that is augmented by an artificial intelligence and machine learning technology that analyzes, predicts, and helps screen our library of strains for drug like molecules. You can learn more about their company today at their website https://azitrainc.com.  Thanks again for those of you that joined this event and please note that I intend on hosting the Phoenix events on the last Thursday of each month going forward with a list of evolving companies that the Tribe is seeking to meet. If you want a direct invitation going forward for Scottsdale or other cities where the Tribe is hosting events, then please let me know.  Here’s a little more info this week’s speaker.

Travis Whitfill (pictured above) is a serial biotech entrepreneur. He is the is the cofounder and Chief Operating Officer at Azitra. His background began in molecular biology and biochemistry after receiving scientific training at the MD Anderson Cancer Center, Duke University, and Yale University. Previously, Travis was a Partner at Bios Partners, which is biotech-focused venture capital fund. He has sat on the board of several portfolio companies, including 410 Medical, Immusoft Corporation, IN8bio (NASDAQ: INAB) and SIRPant Immunotherapeutics. He also is an Assistant Professor Adjunct in the Departments of Pediatrics and Emergency Medicine at Yale University. Mr. Whitfill has led numerous grant-funded projects, holds nearly a dozen patents, and has co-authored over 50 publications.

He was on Forbes’ 30 under 30 list (healthcare) in 2018. Mr. Whitfill received degrees from Yale University (MPH), University College London (MPhil), Dallas Baptist University (BS), and is finishing a PhD from University College London in innovation and economics.


As for the broad markets this week, stocks moved significantly lower  over the course of this holiday shortened 4-day trading session week. The downward driving move came in concert with the Fed’s Chair Jerome Powell delivering his thoughts to the House Committee over a 2-day period confirming primarily that he sees 2 more interest hikes yet this year as he sees that inflation is not under control. He also shared that he does not see the Fed requiring additional requirements for regional banks. However, with the prospects of two additional interest hikes in view, which will most certainly add further stress on the regional banks and mortgage holders alike we saw a decidedly negative move across the banking stocks as The SPDR S&P Regional Banking ETF (KRE) dropped sharply by 9.37% over the last 5-days to close at $39.58 & the SPDR S&P Bank ETF (KBE) fell 7.86% over the last 5-days to close at $34.81. Interestingly, the CBOE Volatility Index (^VIX) closed at $13.44 & down 3.27% over the last 5-days even though it popped 4.11% higher on Friday.

Contributing to investors worries were a number central banks that moved to increase their interest rate this weeks i.e. England, Norges Bank, Swiss National Bank & Turkey. Overall growth concerns seemed to flourish as these rolled out and as the macroeconomic schedule added a number of reports that added to this understanding. However, mixed into the number of reports there were some outlying reports that begged to differ and further confused many. On Tuesday, the Total housing starts report that confirmed a massive 21.7% M/M jump to a seasonally adjusted annual rate of 1.631M. The Total building permits report also showed a solid 5.2% M.M increase to a seasonally adjusted annual rate of 1.491 million. On Wednesday, the MBA Mortgage Applications Index report confirmed a .5% increase as purchase applications moved up 2% & refinancing applications dropped 2%. On Thursday, the Q1 Current Account Balance report came in at -$219.3B. The Initial jobless claims report for the week ending June 17 came in flat at 264k & where the 4-week moving average came in at 255,750. The Continuing jobless claims report for the week ending June 10 fell by 13k to 1.759M. The Existing home sales report showed a .2% M/M rise in May to a seasonally adjusted annual rate of 4.30M, however, sales were down 20.4% Y/Y. The Leading Indicators report confirmed a .7% drop in May. The weekly EIA Natural Gas Inventories report confirmed a 95 bcf build. The weekly EIA Crude Oil Inventories report came in with a 3.83M barrel draw as crude oil prices dropped 3.7% to close at $69.26/bbl over the last 5-days and are now down 13.7% YTD. On Friday, the June IHS Markit Manufacturing PMI dropped again to 46.3 & the Preliminary June IHS Markit Services PMI report came in at lower at 54.1. The preliminary June manufacturing PMI reports for the eurozone, Germany, Japan, and the United Kingdom all came in below the Mendoza Line for growth. As a result, the yield curve diverged slightly over the course of the week with 2-yr note yield moving up 4bps to 4.75% & the 10-yr note yield moved down 1bp to 3.74%. The U.S. Dollar Index moved higher  to close the week at 102.87 this week. 


The S&P 500 closed at 4,348.33 (-1.4%) for the week and is now up 13.3% YTD as 10 out of the 11 sectors closed in the red this week with the health care sector rising .2%, while the real estate sector dropped 4% and energy took the second largest hit dropping 3.5%. Note that sector leadership has begun to exhibit signs of a widening to other sectors as the industrials sector and the materials sector have pushed in the green YTD. 

The Dow 30 closed at 33,727.40 (-1.7%) for the week and is now up 1.8% YTD.  The Walt Disney Company (DIS) closed at $88.10, -5.21% over the last 5-days. Nike (NKE) closed at $109.52, -2.57% over the last 5-days. 3M (MMM, $100.72, -2.98% over the last 5-days) announced that it has reached a $10.3B settlement that will provide these funds over a 13-yr period with a number of U.S. public water systems to resolve water pollution claims tied to ‘forever chemicals’ and which will that will provide these funds over a 13-yr period to test and treat contamination of PFAS.

The Nasdaq closed at 13,492.50 (-1.4%) and is now up 28.9% YTD. Overall the artificial intelligence trade that has been driving a number of tech stock higher slowed down and/or pulled back in most cases this week. The ‘Magnificent Seven’ performed as follows over the last 5-days: which includes Apple (AAPL, $186.68, +.36%), Alphabet (GOOGL $122.34, -.66%, GOOG, $123.02, -2.20%), Microsoft (MSFT, $335.02, -3.76%), Amazon (AMZN, $129.33, -.63%), Meta (META,$288.73, +2.45%), Tesla (TSLA, $260.54, +.27%), and Nvidia (NVDA, $422.09, -1.04%). This so-called group accounts for ~84% of the Nasdaq 100’s ~$4T growth in market cap YTD. Netflix (NFLX) also cooled off after its recent run to close at $424.02, -4.77% over the last 5-days. Netflix’s recent positive move has come as it was widely reported to be gaining subscribers as their tactics to stop password sharing is apparently working. C3 AI (NYSE: AI), the Enterprise AI software application company, hosted an Investor Day on June 22, 2023 in New York City to provide C3 AI investors with a company update while shares of AI dropped a solid 27.99% over the last 5-days to close at $33.39.

As for the biotech sector, the Nasdaq Biotechnology ETF (IBB) closed at $128.50, -2.51% over the last 5-days and is now down 2.13% YTD, the NYSE ARCA Biotech Index (^BTK) closed at 5,381.12, -1.21% over the last 5-days and is now up +1.89% YTD, & the SPDR S&P Biotech ETF (XBI) pulled back to closed at $85.12, -4.56% over the last 5-days, & is now up 2.55% YTD. The 52-week range is is now $72.44-$95.18. Cathie Wood’s ARK Innovation ETF (ARKK) closed at $42.14, -5.39% and is now up 34.89% YTD.  

The small caps on the Russell 2000 closed at 1,821.63 (-2.9%) for the week & is now up 3.4% YTD. The MicroCaps also moved sharply lower this week as the iShares Micro-Cap ETF (IWC) closed at $107.58, -3.73% this week & is now down .23% YTD.  

The iShares U.S. Healthcare ETF (IYH) closed at $278.55, +.12% over the last 5-days and is now down 1.82% YTD.  

From the world of cryptocurrency, Bitcoin (BTC) moved to $30,661.78 & up 14.19% over the course of the last 5-days at the time of the completion of this message. 

Gold prices closed at $1,924, -$37/oz over the last 5-days. Silver prices closed at $22.36, -$1.87/oz over the last 5-days. 

VP Watchlist Updates




Lantern Pharma Inc. (NASDAQ: LTRN, 5.12, +13.37% over the last 5-days) is a clinical-stage biopharmaceutical company using its proprietary RADR® artificial intelligence (“AI”) and machine learning (“ML”) platform to transform the cost, pace, and timeline of oncology drug discovery and development.

On June 12, Lantern announced that the U.S. Food and Drug Administration (FDA) has cleared the investigational new drug (IND) application for LP-184, which is being developed for multiple advanced solid tumors and central nervous system (CNS) cancers. The first-in-human Phase 1A trial for LP-184 is anticipated to launch and dose its first patient during the current quarter. LP-184 is a novel, synthetically-lethal, small molecule that has been developed using insights from Lantern’s AI platform, RADR®. Lantern has been granted multiple Orphan Drug Designations by the FDA for LP-184 in pancreatic cancer, malignant gliomas, and atypical teratoid rhabdoid tumors (ATRT); in addition the FDA granted Rare Pediatric Disease Designation granted for LP-184 in ATRT. The cancer indications being pursued for LP-184 are estimated to have an annual market potential of $11-13 billion; $6-7 billion for solid tumors and $5-6 billion for brain and CNS cancers.

On June 8, Lantern announced it will be leveraging its AI platform, RADR®, in a research collaboration with Bielefeld University (Bielefeld, Germany) to develop antibody-drug conjugates (ADCs) with high therapeutic and antitumor potential. The collaboration will leverage insights from Lantern’s recently developed RADR® AI ADC module in combination with research from Professor Norbert Sewald, Ph.D., the principal investigator for Bielefeld and leader of Magicbullet::reloaded, a European consortium focused on developing novel drug delivery mechanisms, including ADCs. Outcomes from the collaboration are expected to pave the way for next-generation ADCs and other drug conjugates that are designed using AI and that can be developed with potentially higher efficacy, at a faster pace, and with significantly reduced costs. The collaboration with Bielefeld University (Germany) will be led by Professor Norbert Sewald, Ph.D., a leading expert in the synthesis of cryptophycins, development of ADCs, and the coordinator of the “Magicbullet::reloaded” consortium. Lantern is receiving an exclusive and worldwide option to license intellectual property from Bielefeld University related to the collaboration and IP generated from the collaboration. The initial aim of the collaboration will be to synthesize and evaluate novel ADCs linked to cryptophycins, which are promising antitumor molecules, in part because of their potency at ultra-low, picomolar, concentrations. The cryptophycin-ADCs will be tested across multiple cancer cell lines and initial results are expected during 2023. The global ADC market is currently over $4.0 billion and is projected to reach $14.0 billion by 2027.

Learn more about Lantern at their website https://www.lanternpharma.com. 



The multi-billion-dollar global fertility market is predicted to reach approximately US$47.9 billion by 2030, yet remains severely underserved with many patients (upwards of 90% by many estimates) unable to access affordable treatment. INVO Bioscience, Inc. (NASDAQ: INVO) offers the INVOcell solution which provides an advanced, effective and affordable infertility treatment to help increase access to care. INVO is commercially advancing INVOcell through the opening of INVO Centers, opportunistically now pursuing acquisitions of established fertility (IVF) clinics in the U.S., and continuing to offer the technology to existing fertility practices.  Shares INVO closed at $.1650 The 52-wk range is $.15 – $1.65.

On May 15, INVO announced financial results for the quarter ended March 31, 2023 and provided a business update. Steve Shum, CEO of INVO stated, “We made significant progress on nearly every key operational metric during the first quarter, particularly within our three existing INVO Centers in Atlanta, Birmingham and Monterrey achieving record levels of revenue and patient cycles. These three centers combined to generate $646,707 in revenue, an increase of 108% from the first quarter of the prior year and were ahead 46% sequentially from Q4 2022, as patients increasingly recognize and value the remarkable opportunity INVO offers to assist families with affordable fertility options. We are extremely pleased to see the existing clinics nearing break-even and look forward to each of them generating positive cashflows and profits in the near future. Tampa Fertility Institute, our planned INVO Center in Tampa, is progressing with a mid-summer target opening and we are also executing on the early preparation work for an INVO Center in Kansas City. To build on the success we are achieving with our INVO Centers, we expanded our commercialization approach to include the acquisition of established and profitable US IVF clinics and announced the execution of binding agreements to acquire Wisconsin Fertility Institute. We view our acquisition strategy as highly complementary to our ongoing efforts to build new INVO Centers, increase sales of our INVOcell® device and expand adoption of the IVC procedure. We expect this strategy to accelerate our corporate development efforts and our path to profitability, as we integrate IVC alongside IVF. We view these two procedures as highly complementary to each other and to our mission of expanding access and affordability for the millions of people for whom the cost of IVF is out of reach. We look forward to closing the acquisition in the current quarter.”

On April 18, Maxim Group’s Analyst Jason McCarthy, Ph.D. issued a BUY rating on INVO Bioscience (INVO), a commercial-stage fertility company focused on expanding the assisted reproductive technology (ART) marketplace by making fertility care accessible and inclusive to people around the world. His report is titled, “4Q Results and Outlook: Fertility Space Remains Active as INVO Expands Strategy with IVF Clinic Acquisition.” His 12-month Price Target is $3. 


  • Borqs Technologies, Inc. (Nasdaq: BRQS, $.205, -4.21% over the last 5-days), a global provider of 5G wireless solutions, Internet of Things (IoT) solutions, and innovative clean energy, recently provided the following updates on the Company.

On June 13, Borqs Technologies, Inc. (Nasdaq: BRQS), a global provider of 5G wireless and Internet of Things (IoT) solutions, announced its plans to further expand into artificial intelligence, leveraging its deep IoT expertise across industries.Beyond Borqs’ current product line for water and energy reservation for smart city applications, the Company plans to accelerate development of consumer-oriented devices and solutions with artificial intelligence capabilities. Artificial Intelligence of Things (AIoT) is defined as the combination of artificial intelligence (AI) technologies with the Internet of Things (IoT) to achieve more efficient IoT operations, improve human-machine interactions and enhance data management and analytics. Borqs further plans to commercialize products that are currently targeted to be applied in e-health, sports, education, and asset protection. According to a Global Market Insights Report dated May 2023, Artificial Intelligence of Things market size was valued at over USD 9 billion in 2022 and is anticipated to grow at a CAGR of 20% between 2023 and 2032.

  • On April 26, Borqs Technologies published its Letter to Shareholders Regarding the Divestment of Solar Subsidiary. “Dear Shareholders of Borqs Technologies, Inc. The purpose of this letter is to help clarify the proposed divestment of our company’s ownership in Holu Hou Energy, LLC (“HHE”) and the implications that this transaction may have to Borqs and our shareholders. Why the divestment? As we have stated in prior press releases, the Committee on Foreign Investment in the United States (“CFIUS”) has notified our company by a letter dated December 13, 2022, that CFIUS has identified risks to US national security arising as a result of Borqs’s investment in HHE. CFIUS advised us that the national security risks arising as a result of Borqs’s investment transaction with HHE relate to foreign proximity to U.S. military personnel and installations through HHE’s physical access to customers and their facilities, including at off-base military housing. CFIUS therefore required Borqs and HHE to enter into a National Security Agreement with CFIUS, pursuant to which Borqs must divest its interests in HHE. Proactive steps by Borqs. Read the balance here:” 
  • On April 20, Borqs announced that its subsidiary, Holu Hou Energy LLC (HHE), a provider of design-to-service solar plus energy storage systems, has signed a contract to install HHE’s HoluPower energy storage and solar photovoltaic (PV) systems on homes at Lendlease’s Island Palm Communities (IPC) in Honolulu, Hawaii. When completed, the project will be worth well into the nine figures in sales for HHE. Lendlease, a leading real estate and investment group that manages almost 8,000 homes for the U.S. Army on Oahu, is the purchaser of the electricity and the installations will come in the form of HHE’s EnergyCluster, where multiple residential units have their systems connected in an energy network or “cluster.” Excess solar generation from any unit’s system in the network that would normally be lost is directly shared in real time with other connected units that have load above solar generation. The benefit is that the optimized PV and energy storage systems can meet 75-80% or more of the overall residents’ energy needs while not exporting power to the utility grid. Lendlease and HHE began initial planning in 2021, which culminated in constructing a “pilot” project in May 2022. Since then, the pilot has been operating with outstanding results across six residential units. In a typical month, approximately a third of the total generated electricity is shared with other units in the “cluster” thereby solving issues related to vacancy and resident load variability, while proving out the superior value created through a clustered approach versus stand-alone systems. The savings realized by Island Palm Communities through deployment of HHE’s systems is being reinvested to enhance the housing and amenities Lendlease offers to military families on the installation. Additionally, residents now have resilient back-up power that can be utilized during grid outage events. These systems also take a load burden off the Oahu electric grid, which improves overall stability. Each residential unit will have approximately 10kW of PV and 25 kWh of energy storage, with six residences typically being connected in an HHE EnergyShare network. Construction is set to begin summer of 2023, with initial installations at the Aliamanu Military Reservation near Honolulu.


Shares of InMed Pharmaceuticals Inc. (INM), a leader in the research, development and manufacturing of rare cannabinoids, closed at $.935.

  • On June 22, InMed announced safety and efficacy results from its Phase 2 clinical trial, called 755-201-EB (the “Phase 2 Trial”), for the treatment of symptoms related to EB. The purpose of the Phase 2 Trial was to evaluate the safety of INM-755 CBN cream, which consists of the control cream plus the active pharmaceutical ingredient CBN, and obtain preliminary evidence of efficacy in treating symptoms and healing wounds over a 28-day period in patients with EB. All four subtypes of inherited EB, including EB Simplex, Dystrophic EB, Junctional EB, and Kindler Syndrome were accepted into the Phase 2 Trial. The Phase 2 Trial used a within-patient, double-blind design whereby matched index areas were randomized to INM-755 CBN cream or control cream. The Phase 2 Trial enrolled a total of 19 patients. Data from one patient were excluded from efficacy analyses due to a significant protocol deviation. Of the 18 remaining patients whose data were considered reliable for clinical review, 17 were treated for chronic non-wound itch and one patient was treated for wound-related itch. The remaining endpoints (pain, wound healing) could not be analyzed due to too few enrollees with such symptoms. Of the 18 participants assessed, chronic itch improved by a clinically meaningful amount in 12 patients (66.7%). InMed will pursue strategic partnership opportunities for INM-755 in epidermolysis bullosa (“EB”) and other itch-related skin conditions.
  • On June 1, InMed announced that results from a neurodegenerative disease study was presented in a scientific poster at the Canadian Neuroscience Meeting in Montreal from May 28-31, 2023. The InMed sponsored research, entitled “Cannabinoids modulate cytotoxicity and neuritogenesis in Amyloid-beta-treated neuronal cells”, demonstrated the ability of a specific rare cannabinoid (“pCBx”) in InMed’s 900 Series library of potential candidates that reduces amyloid toxicity and tau protein expression while enhancing neuronal cell growth and neuritogenesis markers in vitro, all considered to be important targets in the potential treatment of neurodegenerative diseases such as Alzheimer’s. The research was conducted in the laboratory of Dr. Ujendra Kumar and Dr. Rishi Somvanshi of the faculty of Pharmaceutical Sciences at the University of British Columbia. Studies have shown that cannabinoids, via their endocannabinoid receptors (CB1R and CB2R) that naturally occur in the human body and brain, reduce amyloid-beta (“Aβ”) toxicity, decrease p-tau protein expression and provide neurite outgrowth, thus improving neuronal viability and function. The results presented demonstrate the anti-apoptotic effects of pCBx and its role in neuritogenesis in the cells of neuronal origin and support the role of pCBx as a potential therapeutic intervention in neurodegenerative diseases.

  • On May 31, our sister organization, Tribe Public, hosted a Presentation & Q&A Webinar Event titled “InMed Pharmaceuticals (NASDAQ: INM) Addressing The Increasing Demand For Rare Cannabinoids.” The event was co-hosted by InMed Pharmaceutical’s (NASDAQ: INM) CEO Eric A. Adams, MIBS, & BayMedica’s Jerry P. Griffin, VP, Sales and Marketing. InMed Pharmaceuticals (NASDAQ: INM, $1.34, +6.35%) is a global leader in the development, manufacturing, and commercialization of rare cannabinoids, which is developing a pipeline of rare cannabinoid therapeutics and dedicated to delivering new treatment alternatives to patients that may benefit from cannabinoid-based pharmaceutical drugs. i.e. Alzheimer’s Disease, Glaucoma, & a rare genetic skin disease, Epidermolysis Bullosa (EB). Together with its subsidiary, BayMedica LLC, the Company has unparalleled cannabinoid manufacturing capabilities to serve a spectrum of consumer markets, including pharmaceutical and health and wellness. If you missed this event, then you may now watch the event video at the Tribe Public YouTube Channel by clicking here. 


Eric Adams recently stated, “In the last few months we have seen a noticeable increase in awareness, understanding and adoption of rare cannabinoids in the H&W sector, evidenced by leading companies expanding their product lines to include new formats and formulations using rare cannabinoids such as the non-psychoactive ingredient cannabichromene (“CBC”). We are encouraged by two consecutive periods of significant quarter over quarter revenue growth. We will continue to support growth in a fiscally prudent manner in this relatively nascent market, where product demand can be unpredictable. The combination of a pharmaceutical drug development pipeline, together with a revenue generating commercial operation that will be contributing to extending our cash runway makes InMed a unique company within the rare cannabinoid space.”



  • On March 28, InMed announced it has concluded enrollment of its Phase 2 clinical trial using investigational drug INM-755 cannabinol (“CBN”) cream for the treatment of patients with epidermolysis bullosa (“EB”), a rare genetic skin disease. The Phase 2 study, called INM-755-201-EB, enrolled 19 patients. All four subtypes of inherited EB, including EB Simplex, Dystrophic EB, Junctional EB, and Kindler Syndrome were accepted into the trial. The clinical trial is evaluating the safety of INM-755 cannabinol cream and its preliminary efficacy in treating symptoms of itch, pain, and wound healing in patients with epidermolysis bullosa. The study used a within-patient, double-blind design whereby matched index areas are randomized to INM-755 (cannabinol) cream or vehicle cream as a control. Results from this Phase 2 study of INM-755 CBN cream are expected to be released early calendar Q3 2023. “Enrollment completion of this Phase 2 clinical trial of a cannabinol formulation represents an important milestone for InMed and the scientific community studying rare cannabinoids,” said Eric A. Adams, InMed’s President and CEO. “As a class of compounds, we believe cannabinoids hold tremendous therapeutic potential for their innate interaction with the body, however, to date there have been limited evidence-based studies investigating their effects. Taking a rare cannabinoid formulation through several Ph 1 and Ph 2 clinical trials has been a major undertaking. We look forward to the data read-out in the summer, so we can evaluate our strategic options and next steps.”


Shares of Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need in oncology, with a current focus on breast cancer and radiation-induced lung injury, closed at $.8706, off 1.07% over the last 5-days.

On June 21, Atossa announced that the United States Patent and Trademark Office (USPTO) has granted a new patent (No. 11,680,036) directed to enterically encapsulated endoxifen compositions formulated as a suspension. These include all liquid suspension formulations suitable for oral administration and dispersible tablets, powders, granules, pellets or sprinkles for reconstitution, which are commonly used for pediatric administration. A suspension is a heterogeneous mixture. It differs from a solution, which is a homogeneous mixture, in that the particles in a solution are much smaller and are dissolved in a solvent, therefore staying mixed together. In a suspension, the particles are large, do not dissolve, and will separate. Advantages of suspension formulations may include ease of delivery of low soluble therapeutic agents, increased bioavailability of drug dosage, controlled drug delivery and resistance to degradation. Dr. Steven Quay, Atossa’s President and Chief Executive Officer, “Our new patent covering suspension formulations is important as we continue to learn more about the potential therapeutic role of endoxifen beyond breast cancer and mammographic breast density. Suspension formulations are particularly useful in pediatric applications where drugs are often dosed by weight and delivered via powders or sprinkles mixed with food and dispersible tablets, which are easier for children to ingest compared to tablets.”

On June 12, Atossa announced that the pharmacokinetic (PK) run-in cohort of the Phase 2 EVANGELINE (Endoxifen Versus exemestANe GosEreLIn) study has fully enrolled. EVANGELINE is a randomized non-inferiority trial of Atossa’s patented Selective Estrogen Receptor Modulator (SERM), (Z)-endoxifen, and exemestane plus goserelin as a neoadjuvant treatment for pre-menopausal women with Grade 1 or 2 Estrogen Receptor positive (ER+) / Human Epidermal Growth Factor Receptor 2 negative (HER2-) breast cancer. The PK run-in cohort consists of six patients, all of whom will be treated with (Z)-endoxifen at 40mg/day for four weeks. The goal of the PK run-in cohort is to determine if the 40mg dose delivers steady-state plasma concentrations (Css) between 500 – 1000 ng/mL, which are optimal to target PKCβ1 inhibition and enhance (Z)-endoxifen’s antitumor mechanism of action. Once the optimal dose of (Z)-endoxifen is determined, the Treatment Cohort will commence. Participants in the treatment cohort will receive neoadjuvant treatment for up to six months, followed by surgery. The study is expected to enroll approximately 175 patients at up to 25 sites across the United States.



Atossa’s CEO, Steven Quay, M.D., Ph.D., presented at a Tribe Public even titled “Atossa Therapeutics (NASDAQ: ATOS) Redefining Breast Cancer Prevention and Treatment” on Thursday, May 4, 2023. Dr. Quay provided an update on the clinical development of Atossa’s proprietary Selective Estrogen Receptor Modulator (SERM), (Z)-endoxifen, which is currently being investigated in three separate Phase 2 studies. You may view the event at the following link at the Tribe Public YouTube Channel. .

 



Cytovia Therapeutics aims to accelerate patient access to transformational cell therapies and immunotherapies, addressing several of the most challenging unmet medical needs in cancer. Cytovia focuses on harnessing the innate immune system by developing complementary and disruptive iPSC-derived Natural Killer (iNK) cell and Flex-NK™ bispecific antibody platforms. The company is developing three types of iNK cells: unedited iNK cells, TALEN® gene-edited iNK cells with improved function and persistence, and TALEN® gene-edited iNK cells with chimeric antigen receptors (CAR-iNKs) to improve tumor-specific targeting. The second complementary cornerstone technology is a quadrivalent multifunctional antibody platform designed to engage natural killer cells by targeting NKp46 using Cytovia’s proprietary Flex-NK™ technology. These two technology platforms are being used to develop treatment for patients with solid tumors such as HCC and glioblastoma as well as hematological malignancies such as refractory multiple myeloma. Headquartered in Aventura, FL., Cytovia has research and development laboratories in Natick, MA. The company’s own R&D work is augmented through scientific partnerships with Cellectis, CytoImmune, the Hebrew University of Jerusalem, INSERM, the New York Stem Cell Foundation, the National Cancer Institute, and the University of California San Francisco (UCSF). Cytovia has a partnership with CytoLynx Therapeutics focused on research and development, manufacturing, and commercialization activities in Greater China.

On May 17, Cytovia Therapeutics R&D Team Presented Poster at ASGCT 2023 on GPC3-Targeted TALEN® Gene-Edited CAR-iNK Cell.

On Dec. 9, 2022, Cytovia announced new preclinical data for its CD38-targeted Flex-NK™ bispecific antibody at the American Society of Hematology’s 64th Annual Meeting (ASH 2022) taking place in New Orleans, LA, and virtually December 10-13th, 2022. “We’re delighted to see further progress on our CD38-targeted Flex-NK™ bispecific antibody program, with a pre-clinical package that supports clinical evaluation in 2023,” commented Cytovia CEO Dr. Daniel Teper. “The data presented at ASH suggests that CYT-338, our CD38-targeted Flex-NK™ Bispecific Antibody, has a differentiated profile compared to daratumumab, the leading CD38-targeted monoclonal antibody and that CYT-338 may have the ability to overcome NK cell exhaustion and dysfunction.”  Cytovia believes that by redirecting and activating NK cells to kill myeloma cells, bispecific antibodies have the potential to offer new options for patients not responding to first lines of treatment.”



Shares of ADT Inc. (ADT), the most trusted brand in smart home and small business security, closed at $5.86, 5.02% over the last 5-days. On May 2, ADT reported results for the first quarter of 2023 highlighting strong year-over-year growth in revenue; CSB and Commercial up 7% and 15%, respectively, versus prior year period, maintained record high customer retention and new record high recurring monthly revenue balance, improved capital efficiency with record revenue payback, & continued deleveraging with over $400 million debt reduction expected in 2023.



On June 23, CarMax, Inc. (NYSE:KMX, $86.21, +6.63% over the last 5-days), the nation’s largest retailer of used autos, reported results for the first quarter ended May 31, 2023. Bill Nash, president and chief executive officer stated, “Our deliberate actions are driving improved trends in the business, despite the challenging macro environment. Our unit performance in used, wholesale and consumer and dealer buys all improved sequentially from the year-over-year trends in the second half of fiscal year 2023. We also continued to deliver strong retail and wholesale gross profit per unit along with SG&A reductions. We are prioritizing projects that drive operating efficiencies and create better experiences for our associates and customers. We believe these steps will enable us to come out of this cycle leaner and more effective, while also positioning us for future growth.”


Thanks again for your attention this week. Please continue to share your thoughts, questions, & ideas as we move forward. 

In the meantime, please enjoy the balance of the weekly newsletter’s videos, quotes, updates and let’s find ways to crush it again this year!

Investing & Inspiration

  1. “If everyone is moving forward together, then success takes care of itself.” – Henry Ford
  2. “Hope is like the sun, which, as we journey toward it, casts the shadow of our burden behind us.”– Samuel Smiles
  3. “Patriotism is supporting your country all the time, and your government when it deserves it.” – Mark Twain
  4. “What would life be if we had no courage to attempt anything?” – Vincent Van Gogh
  5. “The biggest risk is not taking any risk… In a world that is changing really quickly, the only strategy that is guaranteed to fail is not taking risks.” – Mark Zuckerberg
  6. “Our lives improve only when we take chances – and the first and most difficult risk we can take is to be honest with ourselves.” – Walter Anderson
  7. “Action is the foundational key to all success.” – Pablo Picasso
  8. “Success is never final, failure is never fatal. It’s courage that counts.” – John Wooden
  9. “Innovation distinguishes between a leader and a follower.” – Steve Jobs
  10. “All the art of living lies in a fine mingling of letting go and holding on.” – Havelock Ellis
  11. “The size of your success is measured by the strength of your desire; the size of your dream; and how you handle disappointment along the way.” – Robert Kiyosaki
  12. “O, wind, if winter comes, can spring be far behind?” – Percy Bysshe Shelley
  13. “Patience is a virtue, and I’m learning patience. It’s a tough lesson.” – Elon Musk
  14. “Be true to your work, your word, and your friend.” – John Boyle O’Reilly
  15. “Believe in yourself! Have faith in your abilities! Without a humble but reasonable confidence in your own powers you cannot be successful or happy.” – Norman Vincent Peale
  16. “Surprise is the greatest gift which life can grant us.” – Boris Pasternak
  17. “Logic will get you from A to B. Imagination will take you everywhere.” – Albert Einstein
  18. “It is the fight alone that pleases us, not the victory.” – Blaise Pascal
  19. “Do exactly what you would do if you felt most secure.” – Meister Eckhart
  20. “Life lived for tomorrow will always be just a day away from being realized.” – Leo Buscaglia
  21. “Wisdom is oftentimes nearer when we stoop than when we soar.” – Wordsworth
  22. “Take chances, make mistakes. That’s how you grow. Pain nourishes your courage. You have to fail in order to practice being brave.” – Mary Tyler Moore
  23. “A single twig breaks, but the bundle of twigs is strong.” – Tecumseh
  24. “If one does not know to which port one is sailing, no wind is favorable.” – Lucius Annaeus Seneca
  25. “There is little that can withstand a man who can conquer himself.” – Louis XIV
  26. “The limits of the possible can only be defined by going beyond them into the impossible.” – Arthur C. Clarke
  27. “Be faithful in small things because it is in them that your strength lies.” – Mother Teresa
  28. “The future rewards those who press on. I don’t have time to feel sorry for myself. I don’t have time to complain. I’m going to press on.” – Barack Obama
  29. “By three methods we may learn wisdom: First, by reflection, which is noblest; Second, by imitation, which is easiest; and third by experience, which is the bitterest.” – Confucius
  30. “No man was ever wise by chance.” – Lucius Annaeus Seneca
  31. “Progress is man’s ability to complicate simplicity.” – Thor Heyerdahl
  32. “It is not in the stars to hold our destiny but in ourselves.” – William Shakespeare

  33. “It does not matter how slowly you go as long as you do not stop.” – Confucius

  34. “I want to put a ding in the universe.” – Steve Jobs

  35. “Research is creating new knowledge.” – Neil Armstrong

  36. “The reward for work well done is the opportunity to do more.” – Jonas Salk
  37. “Man is a creative retrospection of nature upon itself.” – Karl Wilhelm Friedrich Schlegel
  38. “There’s something about taking a plow and breaking new ground. It gives you energy.” – Ken Kesey

  39. “Success seems to be largely a matter of hanging on after others have let go.” – William Feather

  40. “The essential conditions of everything you do must be choice, love, passion.” – Nadia Boulanger

  41. “More business is lost every year through neglect than through any other cause.” – Rose Kennedy

  42. “Give me a lever long enough and a fulcrum on which to place it, and I shall move the world.” – Archimedes

  43. “A person who won’t read has no advantage over one who can’t read.” – Mark Twain

  44. “The best way out is always through.” – Robert Frost

  45. “Start by doing what’s necessary; then do what’s possible; and suddenly you are doing the impossible.” – Francis of Assisi

  46. “Without labor nothing prospers.” – Sophocles

  47. “Intellectuals solve problems, geniuses prevent them.” – Albert Einstein

  48. “This is the precept by which I have lived: Prepare for the worst; expect the best; and take what comes.” – Hannah Arendt

  49. “The best and most beautiful things in the world cannot be seen or even touched – they must be felt with the heart.” – Helen Keller

  50. “He who is brave is free.” – Lucius Annaeus Seneca

  51. “When something is important enough, you do it even if the odds are not in your favor.” – Elon Musk

  52. “I choose a block of marble and chop off whatever I don’t need.” – Auguste Rodin

  53. “Hope is the only bee that makes honey without flowers.” – Robert Green Ingersoll

  54. “He who knows that enough is enough will always have enough.” – Lao Tzu

  55. “Plans to protect air and water, wilderness and wildlife are in fact plans to protect man.” – Stewart Udall

  56. “In order to carry a positive action we must develop here a positive vision.” – Dalai Lama

  57. “A hero is someone who understands the responsibility that comes with his freedom.” – Bob Dylan
  58. “Inflation destroys savings, impedes planning, and discourages investment. That means less productivity and a lower standard of living.” – Kevin Brady
  59. “If we give something positive to others, it will return to us. If we give negative, that negativity will be returned.” – Allu Arjun
  60. “A good plan violently executed now is better than a perfect plan executed next week.” ~ George S. Patton
  61. “You must do the things you think you cannot do.”- Eleanor Roosevelt
  62. “Success is dependent on effort.” – Sophocles
  63. “Nobody who ever gave his best regretted it.” – George Halas
  64. “Lots of people want to ride with you in the limo, but what you want is someone who will take the bus with you when the limo breaks down.” ~ Oprah Winfrey
  65. “And when I breathed, my breath was lightning.” – Black Elk
  66. “Moderation is the silken string running through the pearl chain of all virtues.” – Joseph Hall
  67. “You are the sum total of everything you’ve ever seen, heard, eaten, smelled, been told, forgot – it’s all there. Everything influences each of us, and because of that I try to make sure that my experiences are positive.” – Maya Angelou
  68. “If you want a guarantee, buy a toaster.” – Clint Eastwood
  69. “We are an impossibility in an impossible universe.” – Ray Bradbury
  70. “If you think in terms of a year, plant a seed; if in terms of ten years, plant trees; if in terms of 100 years, teach the people.” – Confucius
  71. “I’d rather attempt to do something great and fail than to attempt to do nothing and succeed.” – Robert H. Schuller
  72. “Do your little bit of good where you are; it’s those little bits of good put together that overwhelm the world.” Desmond Tutu
  73. “It takes considerable knowledge just to realize the extent of your own ignorance.” – Thomas Sowell
  74. “Do not dwell in the past, do not dream of the future, concentrate the mind on the present moment.” – Buddha”
  75. Surprise is the greatest gift which life can grant us.” –  Boris Pasternak
  76. “Trust in dreams, for in them is hidden the gate to eternity.” – Khalil Gibran 
  77. “Always be yourself, express yourself, have faith in yourself, do not go out and look for a successful personality and duplicate it.” – Bruce Lee
  78. “All life is an experiment. The more experiments you make the better.” – Ralph Waldo Emerson
  79. “There are no secrets to success. It is the result of preparation, hard work, and learning from failure.” –  Colin Powell
  80. “There is more to life than increasing its speed.” – Mahatma Gandhi
  81. “Your attitude is like a box of crayons that color your world. Constantly color your picture gray, and your picture will always be bleak. Try adding some bright colors to the picture by including humor, and your picture begins to lighten up.” – Allen Klein
  82. “Definiteness of purpose is the starting point of all achievement.” – W. Clement Stone
  83. “Success usually comes to those who are too busy to be looking for it.” – Henry David Thoreau
  84. “In matters of truth and justice, there is no difference between large and small problems, for issues concerning the treatment of people are all the same.” – Albert Einstein
  85. “Life is too short for long-term grudges.” – Elon Musk
  86. “There cannot be a crisis next week. My schedule is already full.” – Henry Kissinger
  87. “Success consists of getting up just one more time than you fall.” – Oliver Goldsmith
  88. “The Earth is the cradle of humanity, but mankind cannot stay in the cradle forever.” – Konstantin Tsiolkovsky
  89. “Ours is a world of nuclear giants and ethical infants. We know more about war that we know about peace, more about killing that we know about living.” – Omar N. Bradley
  90. “Beauty surrounds us, but usually we need to be walking in a garden to know it.” – Rumi
  91. “But man is not made for defeat. A man can be destroyed but not defeated.” – Ernest Hemingway
  92. “Don’t watch the clock; do what it does. Keep going.” – Sam Levenson
  93. “Let there be work, bread, water and salt for all.” – Nelson Mandela
  94. “The social object of skilled investment should be to defeat the dark forces of time and ignorance which envelope our future.” – John Maynard Keynes
  95. “A successful society is characterized by a rising living standard for its population, increasing investment in factories and basic infrastructure, and the generation of additional surplus, which is invested in generating new discoveries in science and technology.” – Robert Trout
  96. “I know not with what weapons World War III will be fought, but World War IV will be fought with sticks and stones.” – Albert Einstein
  97. “It is the fight alone that pleases us, not the victory.” – Blaise Pascal
  98. “If you can’t describe what you are doing as a process, you don’t know what you’re doing.” – W. Edwards Deming
  99. “Never interrupt your enemy when he is making a mistake.” – Napoleon Bonaparte
  100. “Be sure you put your feet in the right place, then stand firm.” – Abraham Lincoln
  101. “Without investment there will not be growth, and without growth there will not be employment.” – Muhtar Kent
  102. “You have to do your own growing no matter how tall your grandfather was.” – Abraham Lincoln
  103. “Victory has a thousand fathers, but defeat is an orphan.” – John F. Kennedy
  104. “Delete the negative; accentuate the positive!” – Donna Karan
  105. “It’s crazy how fast time flies and how things progress.” – Nathan Chen
  106. “The world is a dangerous place to live; not because of the people who are evil, but because of the people who don’t do anything about it.” – Albert Einstein
  107. “Life isn’t about finding yourself. Life is about creating yourself.” – George Bernard Shaw
  108. “Everything has beauty, but not everyone sees it.” – Confucius
  109. “A man must be big enough to admit his mistakes, smart enough to profit from them, and strong enough to correct them.” – John C. Maxwell
  110. “Walking with a friend in the dark is better than walking alone in the light.” – Helen Keller
  111. “A man who dares to waste one hour of time has not discovered the value of life.” – Charles Darwin
  112. “The greater danger for most of us lies not in setting our aim too high and falling short; but in setting our aim too low, and achieving our mark.” – Michelangelo
  113. “Progress is man’s ability to complicate simplicity.” – Thor Heyerdahl
  114. “I like to encourage people to realize that any action is a good action if it’s proactive and there is positive intent behind it.” – Michael J. Fox
  115. “Nothing is impossible, the word itself says ‘I’m possible’!” – Audrey Hepburn
  116. “But investment in space stimulates society, it stimulates it economically, it stimulates it intellectually, and it gives us all passion.” – Bill Nye
  117. “Bitcoin, in the short or even long term, may turn out be a good investment in the same way that anything that is rare can be considered valuable. Like baseball cards. Or a Picasso.” – Andrew Ross Sorkin
  118. “Life is a tragedy when seen in close-up, but a comedy in long-shot.” – Charlie Chaplin
  119. “No matter what you’re going through, there’s a light at the end of the tunnel and it may seem hard to get to it but you can do it and just keep working towards it and you’ll find the positive side of things.” – Demi Lovato
  120. “Infrastructure investment in science is an investment in jobs, in health, in economic growth and environmental solutions.” – Oren Etzioni
  121. “Educating our children and giving them the skills they need to compete in a global economy is a smart investment in our country’s future.” – Sheldon Whitehouse
  122. “Know thy self, know thy enemy. A thousand battles, a thousand victories.” – Sun Tzu
  123. “If one does not know to which port one is sailing, no wind is favorable.” – Lucius Annaeus Seneca
  124. “Beware of missing chances; otherwise it may be altogether too late some day.” – Franz Liszt
  125. “The sofa is a really important investment for anybody, and I don’t mean financially. You need to find a really great sofa that can transition with you, and you can build from there.” – Jeremiah Brent
  126. “There is no investment you can make which will pay you so well as the effort to scatter sunshine and good cheer through your establishment.” – Orison Swett Marden
  127. “Nothing in life is to be feared, it is only to be understood. Now is the time to understand more, so that we may fear less.” – Marie Curie
  128. “There is little that can withstand a man who can conquer himself.” – Louis XIV
  129. “In tennis, you strike a ball just after the rebound for the fastest return. It’s the same with investment.” – Masayoshi Son
  130. “A camel makes an elephant feel like a jet plane.” – Jackie Kennedy
  131. “The advance of technology is based on making it fit in so that you don’t really even notice it, so it’s part of everyday life.” – Bill Gates
  132. “Success depends upon previous preparation, and without such preparation there is sure to be failure.” – Confucius, Chinese 
  133. “Coming together is a beginning; keeping together is progress; working together is success.” – Edward Everett Hale
  134. “Never do anything against conscience even if the state demands it.”– Albert Einstein
  135. “Education is not only a ladder of opportunity, but it is also an investment in our future.” – Ed Markey
  136. “The true measure of a man is how he treats someone who can do him absolutely no good.” – Samuel Johnson
  137. “In my view, the biggest investment risk is not the volatility of prices, but whether you will suffer a permanent loss of capital. Not only is the mere drop in stock prices not risk, but it is an opportunity. Where else do you look for cheap stocks?” – Li Lu
  138. “A successful society is characterized by a rising living standard for its population, increasing investment in factories and basic infrastructure, and the generation of additional surplus, which is invested in generating new discoveries in science and technology.” – Robert Trout
  139. “The best preparation for tomorrow is doing your best today.” – H. Jackson Brown, Jr.
  140. “Friendship marks a life even more deeply than love. Love risks degenerating into obsession, friendship is never anything but sharing.” – Elie Wiesel
  141. “Investing in women’s lives is an investment in sustainable development, in human rights, in future generations – and consequently in our own long-term national interests.” – Liya Kebede
  142. “Success isn’t measured by money or power or social rank. Success is measured by your discipline and inner peace.” – Mike Ditka
  143. “No matter how many goals you have achieved, you must set your sights on a higher one.” – Jessica Savitch 
  144. “Start where you are. Use what you have. Do what you can.”– Arthur Ashe
  145. “The secret of getting ahead is getting started.” – Mark Twain
  146. “The amount of work and the amount of both physical and emotional investment it takes to get to the top.” – Drew Bledsoe

Videos

Stay Informed. Stay Competitive.

Vista Partners offers an exclusive newsletter and content with daily, weekly, monthly and quarterly investing ideas, strategies, and marketing insights.

We value your privacy and will never share your information.

Recent Posts

VP Watchlist

Trending Posts